ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Neoplasm Metastasis

Lung Cancer trials near Salt Lake City, UT, USA:

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Salt Lake City, Utah, United States and 30 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 210 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 254 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Salt Lake City, Utah, United States and 18 other locations

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of ...

Enrolling
Large Cell Neuroendocrine Carcinoma of the Lung
Small-Cell Lung Cancer (SCLC)
Drug: 225Ac-ABD147

Phase 1

Abdera Therapeutics Inc.

Salt Lake City, Utah, United States and 4 other locations

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung...

Active, not recruiting
Relapsed Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

Pharma Mar

Salt Lake City, Utah, United States and 210 other locations

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Salt Lake City, Utah, United States and 117 other locations

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins...

Enrolling
Non-Small Cell Lung Cancer
EGFR/HER2 Exon 20 Insertion Mutation
Drug: STX-721 (3 dose levels)
Drug: STX-721 (Escalated)

Phase 1, Phase 2

Antares Therapeutics, Inc

Salt Lake City, Utah, United States and 20 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study i ...

Enrolling
Lung Cancer, Non-squamous, Non-small Cell
Drug: carboplatin
Drug: zongertinib

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Salt Lake City, Utah, United States and 169 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) ex...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Salt Lake City, Utah, United States and 207 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems